Smith vs Wolf
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Result | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
J.J. Wolf | Lost | $73 | — | — | — | — | — | — | |
Jeffrey John Wolf Winner | Won | $597.2K | — | — | — | — | — | — | |
Colton Smith | Lost | $887.6K | — | — | — | — | — |
AI-generated summary, may be inaccurate.
This market concerns the Round of 32 clash between Colton Smith and J.J. Wolf at the ATP Challenger Bloomfield Hills on July 21, 2026. On Polymarket, the market resolves to the player who advances, while on Kalshi it is framed as a Yes/No question on whether Colton Smith wins. The match has since been played, and the result is unambiguous: J.J. Wolf won the match 7-6(1) 6-3, making the outcome a foregone conclusion at snapshot time. The pricing across platforms reflects this settled result almost entirely. Polymarket has J.J. Wolf at 99.9% and Colton Smith at just 2.0%, while Kalshi prices Smith's win at 1.0% and Wolf's (framed as "Jeffrey John Wolf") at 99.0% — a 1.0-percentage-point spread on the Smith side being the only notable cross-platform discrepancy. Wolf entered as a protected ranking (PR) entrant, holding a career-high ATP singles ranking of No. 39, achieved in February 2023, giving him a considerable pedigree advantage over Smith despite a ranking slip since. Their only prior meeting went to Smith at the 2025 Cleveland Challenger semifinals, 7-6(7) 6-1, but that head-to-head edge proved immaterial here. The Cranbrook Tennis Classic in Bloomfield Hills is a Challenger 125 event in 2026, carrying significant points — context that underlines Wolf's motivation to advance. With a 99.9%/99.0% consensus and the match already completed, both Polymarket and Kalshi are aligned on a near-certain Wolf resolution, with the negligible 1.0-point spread on Smith being the only residual cross-platform discrepancy.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.